Valganciclovir as preemptive therapy for cytomegalovirus in cytomegalovirus-seronegative liver transplant recipients of cytomegalovirus-seropositive donor allografts
- 1 February 2008
- journal article
- clinical trial
- Published by Ovid Technologies (Wolters Kluwer Health) in Liver Transplantation
- Vol. 14 (2), 240-244
- https://doi.org/10.1002/lt.21362
Abstract
The efficacy of valganciclovir as preemptive therapy for the prevention of cytomegalovirus (CMV) disease and its impact on indirect sequelae of CMV were assessed in recipient‐negative/donor‐positive (R−/D+) liver transplant recipients. Of 187 consecutive liver transplant recipients at our institution since July 2001, 36 (19.2%) belonged to the R−/D+ group. Surveillance tests for CMV were performed on all patients at weeks 2, 4, 6, 8, 10,12, and 16. In all, 27 patients with asymptomatic viremia received preemptive therapy with valganciclovir. At a total follow‐up of 62.8 patient years (median: 19 months, range: 3 months to 5.6 years), no episodes of CMV disease were documented in these patients. The incidence of rejection, retransplantation, and bacterial or fungal infections and the probability of survival did not differ for R−/D+ patients and all non‐R−/D+ patients treated preemptively with valganciclovir (P > 0.20 for all variables). Thus, preemptive therapy with valganciclovir in R−/D+ patients was not associated with CMV disease during the period of surveillance monitoring or at anytime thereafter (late‐onset CMV disease). The indirect outcomes with the use of valganciclovir in R−/D+ patients were comparable to the outcomes of other subgroups of liver transplant recipients receiving preemptive therapy. Liver Transpl 14:240–244, 2008. © 2008 AASLD.Keywords
This publication has 14 references indexed in Scilit:
- Preventing Post–Organ Transplantation Cytomegalovirus Disease with Ganciclovir: A Meta‐Analysis Comparing Prophylactic and Preemptive TherapiesClinical Infectious Diseases, 2006
- Valganciclovir Preemptive Therapy for the Prevention of Cytomegalovirus Disease in High-Risk Seropositive Solid-Organ Transplant RecipientsTransplantation, 2006
- Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral ProphylaxisTransplantation, 2006
- Does Valganciclovir Hydrochloride (Valcyte) Provide Effective Prophylaxis Against Cytomegalovirus Infection in Liver Transplant Recipients?Transplantation Proceedings, 2005
- Efficacy and Safety of Valganciclovir vs. Oral Ganciclovir for Prevention of Cytomegalovirus Disease in Solid Organ Transplant RecipientsAmerican Journal of Transplantation, 2004
- CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1Transplantation, 2000
- The Independent Role of Cytomegalovirus as a Risk Factor for Invasive Fungal Disease in Orthotopic Liver Transplant RecipientsAmerican Journal Of Medicine, 1997
- Primary Cytomegalovirus Infection in Liver Transplant Recipients: Comparison of Infections Transmitted Via Donor Organs and Via TransfusionsClinical Infectious Diseases, 1996
- Cytomegalovirus Infection Following Liver Transplantation: Review of the LiteratureClinical Infectious Diseases, 1996
- Cytomegalovirus infection and disease after liver transplantationDigestive Diseases and Sciences, 1992